# A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

> **NCT02440685** · PHASE1,PHASE2 · TERMINATED · sponsor: **Asana BioSciences** · enrollment: 51 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Follicular
- Cancer
- Neoplasm
- Tumor
- Lymphoma, Malignant
- Lymphoma, B-cell
- Lymphoma, Non-Hodgkin
- B-Cell Chronic Lymphocytic Leukemia
- B-Cell Leukemia, Chronic
- B-Lymphocytic Leukemia, Chronic
- Chronic Lymphocytic Leukemia
- Leukemia, Lymphocytic, Chronic
- Leukemia, Lymphocytic, Chronic, B Cell
- Myelofibrosis
- Chronic Idiopathic Myelofibrosis
- Idiopathic Myelofibrosis
- Lymphoma, T Cell, Peripheral
- Peripheral T-Cell Lymphoma
- T-Cell Lymphoma, Peripheral

## Interventions

- **DRUG:** ASN002 Dose Escalation
- **DRUG:** ASN002 RD

## Key facts

- **NCT ID:** NCT02440685
- **Lead sponsor:** Asana BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2018-06
- **Final completion:** 2018-07
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440685, "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02440685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*